TO TORNTPHARM
Torrent Pharmaceuticals Q1 2026
TOTORNTPHARM

Torrent Pharmaceuticals Q1 FY26 results (Apr–Jun 2025) and concall

Healthcare · Concall AI · Call held 28 Jul 2025

Management summary

  • Torrent Pharma started FY26 with steady double-digit growth led by its core branded markets in India and Brazil.
  • While Germany faced temporary supply disruptions from a third-party partner, the US business showed recovery with strong constant currency growth and narrowing losses.
  • Management expressed high confidence in maintaining a 32.9% margin floor for the remainder of the fiscal year.

Source: Inve concall analysis and management guidance record.

What they filed

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26
Revenue2,377 2,433 2,616
EBITDA887 868 979
Net profit485 474 551
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Margin

  • Adjusted EBITDA Margin Margin · FY26 · High confidence 32.9%

Headcount

  • India Field Force (MRs) Headcount · by end of FY26 · High confidence 6,900-7,000

    From 6,400 today

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

1 direct
Germany Supply Disruption Partial
Neha, unfortunately, I won't make a prediction, at least a couple of quarters... we are kind of a little bit hostage to the situation in the sense it's not within our direct control.

Reveals that 75% of the Germany business relies on third-party products, creating a significant external dependency risk.

Asked by Neha Manpuria

US Profitability Timeline Direct
Yes, Neha, it's still not profitable. It'll take some while before we get into the profitable zone post R&D.

Confirms that despite 16% CC growth, the US segment is still a drag on consolidated net profit due to R&D costs.

Asked by Neha Manpuria

Unlock risks & concerns, Q2 FY26 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 3 risks, concerns & management red flags
  • Watchlist triggers for Q2 FY26
  • +3 more guidance targets & verbatim management quotes
  • +1 more analyst Q&A exchange & evasion checks
  • Full section-by-section call narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image